Tesamorelin is the only full-length GHRH(1-44) analog with N-terminal trans-3-hexenoic acid protection against DPP-IV. The most physiologically complete GHRH receptor agonist for visceral fat and hepatic lipid research.
Tesamorelin is a synthetic analog of the complete 44-amino acid human GHRH sequence, modified with a trans-3-hexenoic acid group at the N-terminus. This lipophilic modification shields the vulnerable Tyr1-Ala2 dipeptide bond from dipeptidyl peptidase-IV (DPP-IV) enzymatic cleavage — the primary inactivation pathway for native GHRH — while preserving the entire native amino acid sequence. Tesamorelin is therefore unique among GHRH analogs: it is the only available compound that provides full-length, unsubstituted GHRH receptor engagement with enhanced metabolic stability.
The physiological significance of the full 44-amino acid sequence is a matter of active research. While the N-terminal 29 residues contain the receptor-binding domain, residues 30-44 may influence receptor dwell time, membrane partitioning kinetics, and tissue distribution. Tesamorelin produces GHRH receptor activation that maintains all normal physiological feedback mechanisms: somatostatin inhibition, GH autofeedback, and circadian rhythmicity — distinguishing it from DAC-conjugated forms that override these regulatory systems.
Published research has extensively documented Tesamorelin’s effects on visceral adipose tissue biology and hepatic lipid metabolism. The peptide has been studied in models of trunk fat accumulation, hepatic steatosis, IGF-1 axis dynamics, and age-related GH decline. The combination of enhanced stability with physiological signaling fidelity makes Tesamorelin the preferred research tool when investigators require the most biologically representative GHRH receptor stimulation.
Supplied as a lyophilized powder with ≥99% purity. Store at -20°C desiccated. For endocrinology and metabolic research only.